You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

State

Any tobaccob

Combustible tobacco productsc

Cigarettesd

Cigars

Regular pipesf

Water pipes/

E-cigarettesh

Smokeless tobaccoi

% (95% CI)

National 15.4 (15.1–15.6) 13.0 (12.8–13.3) 11.4 (11.2–11.6) 2.1 (2.0–2.2) 0.3 (0.2–0.3) 0.4 (0.4–0.5) 2.3 (2.2–2.4) 1.4 (1.4–1.5)
Alabama 21.6 (19.6–23.6) 16.7 (15.1–18.4) 15.2 (13.6–16.8) 2.0 (1.3–2.7) j j 3.4 (2.6–4.3) 3.9 (3.2–4.7)
Alaska 18.4 (15.7–21.1) 16.5 (13.8–19.1) 14.3 (11.8–16.8) 2.4 (1.5–3.4) j j 2.2 (1.1–3.3) 2.2 (1.3–3.1)
Arizona 14.4 (12.7–16.2) 12.3 (10.8–13.8) 10.5 (9.1–11.9) 2.1 (1.5–2.8) j j 3.4 (2.3–4.5) 0.9 (0.5–1.2)
Arkansas 21.1 (17.7–24.6) 17.3 (14.4–20.2) 15.5 (12.7–18.4) 2.5 (1.7–3.3) j j 2.5 (1.6–3.4) 3.5 (2.5–4.5)
California 10.2 (9.5–10.8) 9.0 (8.4–9.7) 7.5 (7.0–8.1) 1.5 (1.2–1.7) 0.2 (0.1–0.3) 0.5 (0.3–0.7) 1.6 (1.3–2.0) 0.4 (0.3–0.5)
Colorado 14.8 (12.1–17.6) 11.5 (9.6–13.5) 9.9 (8.0–11.9) 1.7 (0.8–2.5) j j 3.2 (2.1–4.4) j
Connecticut 12.9 (10.6–15.3) 11.5 (9.3–13.7) 9.4 (7.4–11.3) 2.7 (1.6–3.8) j j 2.0 (1.0–3.1) j
Delaware 13.4 (11.1–15.8) 12.6 (10.2–14.9) 10.7 (8.6–12.8) 2.2 (1.1–3.2) j j 1.4 (0.8–2.1) j
District of Columbia 14.0 (12.4–15.6) 13.2 (11.6–14.8) 9.9 (8.5–11.3) 2.6 (1.8–3.3) j 2.0 (1.4–2.7) 1.3 (0.8–1.8) 0.4 (0.2–0.6)
Florida 13.9 (12.9–14.9) 12.4 (11.5–13.3) 10.6 (9.7–11.5) 2.1 (1.7–2.5) 0.4 (0.2–0.6) 0.3 (0.2–0.4) 1.7 (1.2–2.1) 0.8 (0.5–1.1)
Georgia 16.2 (14.6–17.9) 14.1 (12.5–15.6) 12.0 (10.5–13.5) 2.3 (1.7–2.9) j 0.7 (0.4–1.1) 2.2 (1.5–3.0) 1.2 (0.6–1.7)
Hawaii 10.8 (8.9–12.7) 9.1 (7.4–10.8) 8.7 (7.0–10.3) 0.7 (0.3–1.1) 0 (0.0–0.0) j 2.7 (1.6–3.9) j
Idaho 16.3 (14.3–18.2) 12.4 (10.7–14.1) 10.8 (9.3–12.3) 1.7 (1.1–2.2) j j 2.8 (2.1–3.6) 3.2 (2.1–4.3)
Illinois 15.7 (14.1–17.3) 14.0 (12.5–15.6) 12.2 (10.7–13.7) 2.2 (1.6–2.8) j j 2.3 (1.8–2.8) 1.1 (0.6–1.5)
Indiana 20.0 (17.3–22.6) 16.8 (14.4–19.3) 14.7 (12.3–17.2) 2.9 (2.0–3.7) j j 3.0 (2.2–3.8) 2.1 (1.4–2.7)
Iowa 20.3 (17.3–23.4) 17.6 (14.6–20.7) 15.9 (13.2–18.6) 2.7 (1.7–3.6) j j 3.1 (2.1–4.1) 2.2 (1.5–2.9)
Kansas 18.6 (15.4–21.7) 14.9 (12.5–17.3) 12.3 (10.1–14.5) 3.3 (2.3–4.4) j j 2.7 (1.4–4.1) 2.3 (1.6–2.9)
Kentucky 24.8 (22.1–27.5) 20.4 (18.0–22.8) 18.3 (15.7–20.9) 2.4 (1.1–3.6) j j 3.5 (2.1–4.9) 4.3 (2.3–6.2)
Louisiana 18.9 (16.5–21.2) 17.0 (14.9–19.1) 14.9 (12.9–16.9) 2.8 (2.1–3.5) j j 1.7 (1.0–2.3) 1.5 (1.0–2.1)
Maine 20.2 (17.7–22.6) 17.9 (15.7–20.2) 15.9 (13.7–18.0) 2.6 (1.4–3.7) j j 3.3 (1.9–4.7) 0.9 (0.4–1.5)
Maryland 14.4 (12.4–16.5) 12.4 (10.4–14.3) 9.9 (8.2–11.5) 2.5 (1.6–3.3) j j 2.2 (1.5–3.0) j
Massachusetts 11.2 (9.7–12.8) 10.0 (8.5–11.4) 8.4 (7.0–9.7) 1.7 (1.2–2.2) j j 1.8 (1.2–2.4) j
Michigan 18.0 (16.1–20.0) 16.3 (14.4–18.2) 14.4 (12.6–16.2) 2.3 (1.7–2.9) j j 1.9 (1.4–2.5) 1.4 (0.9–1.9)
Minnesota 16.2 (13.5–19.0) 13.9 (11.1–16.8) 11.9 (9.6–14.1) 2.0 (1.1–2.9) j j 1.5 (0.9–2.1) 2.1 (1.4–2.8)
Mississippi 20.6 (19.0–22.2) 17.4 (15.9–18.9) 16.2 (15.0–17.5) 2.5 (1.7–3.2) j j 1.4 (0.9–2.0) 3.2 (2.4–3.9)
Missouri 19.1 (17.0–21.3) 16.0 (13.7–18.4) 13.5 (11.4–15.7) 2.5 (1.7–3.4) j j 2.7 (1.8–3.5) 2.2 (1.3–3.1)
Montana 19.9 (18.2–21.7) 15.8 (14.3–17.3) 14.5 (12.9–16.1) 2.0 (1.3–2.6) 0.2 (0.1–0.3) j 2.4 (1.6–3.1) 3.8 (3.0–4.6)
Nebraska 18.8 (16.9–20.7) 15.7 (13.8–17.6) 13.8 (12.0–15.6) 2.6 (1.7–3.4) j j 3.2 (2.0–4.3) 1.7 (0.9–2.5)
Nevada 15.4 (13.5–17.3) 14.2 (12.4–16.1) 12.4 (10.6–14.1) 1.9 (1.1–2.7) j j 2.0 (1.1–2.9) j
New Hampshire 17.4 (15.2–19.6) 15.5 (13.5–17.5) 12.4 (10.6–14.1) 3.0 (2.1–4.0) j j 2.0 (1.0–3.1) 0.7 (0.3–1.2)
New Jersey 11.7 (10.4–13.1) 10.4 (9.1–11.7) 7.8 (6.6–8.9) 2.5 (1.7–3.2) j 0.8 (0.4–1.3) 2.1 (1.4–2.9) j
New Mexico 15.5 (13.3–17.7) 12.6 (10.6–14.6) 11.2 (9.5–12.9) 1.6 (0.8–2.4) j j 2.5 (1.6–3.4) 1.7 (1.3–2.0)
New York 12.9 (12.0–13.9) 11.2 (10.3–12.2) 9.5 (8.7–10.2) 1.3 (1.0–1.6) 0.2 (0.1–0.2) 0.8 (0.5–1.2) 2.1 (1.7–2.5) 0.5 (0.3–0.8)
North Carolina 18.8 (16.8–20.7) 15.9 (14.3–17.6) 13.6 (12.0–15.1) 2.5 (1.8–3.3) j 0.6 (0.3–0.9) 2.7 (2.1–3.3) 2.1 (1.6–2.7)
North Dakota 22.0 (19.4–24.6) 17.3 (15.1–19.5) 15.8 (13.7–17.9) 2.2 (1.5–2.9) j j 3.2 (2.2–4.1) 4.3 (2.8–5.7)
Ohio 21.6 (20.1–23.0) 18.7 (17.3–20.1) 16.4 (15.1–17.8) 3.1 (2.5–3.8) j j 2.8 (2.1–3.5) 2.1 (1.6–2.6)
Oklahoma 23.6 (21.6–25.6) 17.8 (15.8–19.7) 16.1 (14.2–18.1) 2.4 (1.7–3.2) j j 4.9 (3.8–6.1) 3.4 (2.4–4.4)
Oregon 16.0 (14.0–18.1) 13.2 (11.3–15.0) 11.2 (9.3–13.1) 1.9 (1.1–2.7) j j 3.2 (2.2–4.1) 1.9 (1.2–2.6)
Pennsylvania 18.5 (17.0–20.0) 16.2 (14.8–17.6) 13.7 (12.4–14.9) 2.8 (2.2–3.5) 0.4 (0.2–0.6) j 2.4 (1.8–3.0) 1.8 (1.4–2.3)
Rhode Island 12.9 (10.6–15.3) 11.0 (9.1–12.9) 8.4 (6.8–10.0) 1.9 (1.0–2.8) j j j j
South Carolina 16.5 (14.5–18.5) 14.2 (12.2–16.2) 12.8 (10.9–14.8) 1.8 (1.2–2.4) j j 1.9 (1.3–2.6) 1.6 (1.1–2.2)
South Dakota 20.7 (18.6–22.9) 17.8 (15.5–20.0) 15.5 (13.2–17.7) 2.2 (1.3–3.1) j j 3.5 (2.3–4.7) 2.4 (1.6–3.1)
Tennessee 19.7 (18.2–21.2) 17.3 (15.9–18.7) 15.8 (14.4–17.1) 2.0 (1.4–2.6) j j 2.0 (1.2–2.8) 2.1 (1.6–2.6)
Texas 13.4 (12.6–14.2) 10.8 (10.1–11.6) 9.0 (8.3–9.8) 1.7 (1.3–2.1) 0.1 (0.1–0.2) 0.4 (0.2–0.6) 2.3 (1.9–2.7) 1.5 (1.2–1.8)
Utah 10.7 (8.6–12.8) 7.9 (6.0–9.8) 6.7 (5.0–8.3) 1.0 (0.4–1.5) j j 3.0 (2.1–3.8) 1.4 (0.8–2.0)
Vermont 14.2 (12.3–16.2) 12.5 (10.8–14.2) 10.8 (9.2–12.4) 1.8 (1.1–2.5) j j 1.9 (1.1–2.7) 1.0 (0.4–1.6)
Virginia 14.0 (12.0–16.0) 11.8 (9.9–13.6) 9.6 (7.8–11.4) 2.3 (1.7–3.0) j 0.6 (0.3–0.9) 2.4 (1.7–3.0) 1.3 (0.8–1.7)
Washington 13.7 (11.8–15.7) 10.9 (9.5–12.2) 9.9 (8.7–11.2) 1.4 (0.8–1.9) j j 2.3 (1.5–3.1) 1.7 (0.9–2.5)
West Virginia 29.0 (25.0–32.9) 22.9 (19.8–26.0) 21.3 (18.5–24.1) 2.4 (1.5–3.3) 0.6 (0.3–0.9) j 3.8 (2.9–4.7) 6.3 (4.8–7.8)
Wisconsin 17.8 (15.9–19.7) 14.9 (13.3–16.5) 13.2 (11.7–14.7) 1.9 (1.4–2.3) j j 2.6 (1.6–3.6) 1.8 (1.1–2.6)
Wyoming 22.6 (19.6–25.5) 16.2 (14.2–18.3) 14.2 (12.2–16.2) 2.2 (1.5–2.9) j j 3.7 (2.6–4.7) 5.2 (3.0–7.3)

Table 1. Prevalence of Current Use of Tobacco Products Among Adults Aged ≥18 Years, by State, Tobacco Use Supplement to the Current Population Survey, United States, 2018–2019a

a In this article, “tobacco” refers to commercial tobacco products and not to tobacco used for medicinal and spiritual purposes by some American Indian communities.

b Any tobacco use was defined as use either “every day” or “some days” of at least 1 tobacco product. For cigarettes, users were defined as adults who reported use either “every day” or “some days” and had smoked ≥100 cigarettes during their lifetime.

c Any combustible tobacco use was defined as use either “every day” or “some days” of at least 1 combustible tobacco product: cigarettes; cigars, cigarillos, or filtered little cigars; and pipes, water pipes, or hookah. For cigarettes, users were defined as adults who reported use either “every day” or “some days” and had smoked ≥100 times during their lifetime.

d Adults who currently smoke cigarettes were defined as adults who reported smoking ≥100 cigarettes during their lifetime and now smoked cigarettes “every day” or “some days.”

e Adults who currently smoke cigars were defined as adults who currently reported smoking cigars, cigarillos, or little filtered cigars “every day” or “some days.”

f Adults who currently smoke pipes were defined as adults who reported currently smoking tobacco in a regular pipe “every day” or “some days.”

g Adults who currently smoke waterpipes or hookahs were defined as adults who reported currently smoking tobacco in a waterpipe or hookah “every day” or “some days.”

h Adults who currently use e-cigarettes were defined as adults who reported using e-cigarettes at least once during their lifetime and now use e-cigarettes “every day” or “some days.”

i Current smokeless tobacco product users were defined as adults who reported using chewing tobacco, snuff, dip, snus, or dissolvable tobacco at least once during their lifetime and now use at least 1 of these products “every day” or “some days.”

j Unweighted denominator <50 or relative standard error >30%.

Table 2.  

State

Interested in quittingc

Past-year quit attemptsd

Recent smoking cessatione

Receipt of advice to quitf

Use of cessation counseling and/or medications to quitg

Use of counseling to quith

Use of cessation medications to quiti

% (95% CI)

National 76.6 (75.8–77.4) 51.9 (51.1–52.8) 7.4 (7.0–7.9) 71.8 (70.8–72.9) 34.3 (33.1–35.6) 10.2 (9.5–10.9) 31.0 (29.8–32.2)
Alabama 68.2 (63.5–72.9) 46.1 (39.8–52.4) 5.0 (3.0–7.0) 71.1 (63.3–78.9) 27.7 (23.3–32.1) 6.9 (3.7–10.1) 25.7 (21.4–30.0)
Alaska 72.2 (64.1–80.3) 53.0 (44.8–61.2) 7.8 (3.6–12.0) 72.8 (64.7–80.9) 48.1 (38.1–58.1) 24.0 (12.8–35.2) 44.3 (35.1–53.5)
Arizona 78.4 (72.6–84.2) 53.8 (46.9–60.7) 7.7 (4.7–10.7) 63.5 (54.9–72.1) 31.3 (23.8–38.8) 12.6 (7.1–18.1) 27.7 (20.5–34.9)
Arkansas 72.7 (68.3–77.1) 45.1 (40.0–50.2) 6.8 (3.8–9.8) 65.2 (59.1–71.3) 44.6 (36.5–52.7) 8.8 (4.8–12.8) 41.5 (33.1–49.9)
California 80.0 (76.7–83.3) 54.4 (50.6–58.2) 9.0 (7.0–11.0) 69.0 (64.7–73.3) 30.1 (25.3–34.9) 13.0 (9.6–16.4) 26.7 (22.1–31.3)
Colorado 83.6 (75.7–91.5) 54.2 (45.0–63.4) j 63.3 (51.9–74.7) 29.8 (18.2–41.4) j 27.8 (16.1–39.5)
Connecticut 87.5 (81.0–94.0) 52.0 (41.9–62.1) j 83.5 (75.4–91.6) 44.8 (32.0–57.6) j 38.9 (26.1–51.7)
Delaware 78.4 (69.6–87.2) 57.2 (49.0–65.4) 7.9 (3.9–11.9) 84.4 (77.4–91.4) 30.8 (20.3–41.3) j 27.7 (18.0–37.4)
District of Columbia 77.3 (70.1–84.5) 54.8 (47.8–61.8) 8.5 (4.9–12.1) 76.5 (69.8–83.2) 31.7 (24.0–39.4) 11.3 (6.4–16.2) 27.9 (20.4–35.4)
Florida 73.1 (68.8–77.4) 49.1 (44.9–53.3) 6.7 (4.6–8.8) 72.7 (67.3–78.1) 32.5 (27.0–38.0) 13.7 (9.7–17.7) 28.5 (23.4–33.6)
Georgia 79.2 (74.7–83.7) 44.9 (39.2–50.6) 5.9 (2.7–9.1) 76.3 (69.5–83.1) 27.4 (19.9–34.9) 11.1 (6.6–15.6) 24.8 (17.4–32.2)
Hawaii 78.1 (71.7–84.5) 55.7 (46.0–65.4) j 70.4 (59.1–81.7) 29.1 (17.3–40.9) j 24.9 (14.3–35.5)
Idaho 76.0 (71.1–80.9) 55.4 (49.3–61.5) 9.8 (6.2–13.4) 68.4 (60.8–76.0) 35.0 (25.8–44.2) 8.8 (4.1–13.5) 33.4 (24.4–42.4)
Illinois 77.2 (72.9–81.5) 52.5 (47.9–57.1) 8.3 (5.4–11.2) 73.3 (67.2–79.4) 37.1 (29.9–44.3) 12.0 (8.1–15.9) 31.9 (24.5–39.3)
Indiana 73.9 (69.8–78.0) 54.8 (49.1–60.5) 9.9 (6.8–13.0) 75.1 (67.7–82.5) 36.9 (28.8–45.0) 11.0 (5.5–16.5) 29.8 (22.7–36.9)
Iowa 69.5 (61.8–77.2) 49.9 (44.8–55.0) j 75.0 (66.6–83.4) 38.1 (26.1–50.1) j 35.1 (24.1–46.1)
Kansas 72.5 (65.4–79.6) 52.0 (42.5–61.5) 10.3 (6.2–14.4) 65.5 (55.9–75.1) 27.4 (17.6–37.2) j 27.2 (17.5–36.9)
Kentucky 68.8 (62.0–75.6) 46.3 (41.7–50.9) 4.8 (2.5–7.1) 69.9 (64.8–75.0) 28.8 (20.4–37.2) 7.2 (3.8–10.6) 27.5 (19.3–35.7)
Louisiana 76.0 (71.7–80.3) 55.7 (50.3–61.1) 7.5 (5.6–9.4) 67.0 (61.1–72.9) 32.0 (26.6–37.4) 10.7 (7.2–14.2) 29.2 (23.6–34.8)
Maine 75.4 (69.3–81.5) 54.3 (48.1–60.5) 8.2 (4.5–11.9) 71.5 (62.2–80.8) 45.9 (36.7–55.1) 12.9 (6.8–19.0) 43.1 (34.0–52.2)
Maryland 84.7 (79.0–90.4) 47.8 (38.6–57.0) j 74.3 (64.8–83.8) 38.6 (27.4–49.8) j 35.8 (25.2–46.4)
Massachusetts 77.9 (72.3–83.5) 56.2 (49.5–62.9) 9.8 (5.5–14.1) 77.3 (70.5–84.1) 50.1 (41.0–59.2) 7.6 (3.4–11.8) 47.5 (38.7–56.3)
Michigan 74.0 (67.4–80.6) 52.6 (47.3–57.9) 6.9 (4.1–9.7) 76.3 (70.7–81.9) 36.4 (29.4–43.4) 13.0 (8.3–17.7) 30.1 (24.1–36.1)
Minnesota 77.5 (72.3–82.7) 51.2 (44.7–57.7) 7.2 (4.0–10.4) 74.1 (67.8–80.4) 39.1 (29.8–48.4) j 38.1 (28.5–47.7)
Mississippi 72.1 (67.1–77.1) 48.8 (41.0–56.6) 6.8 (3.9–9.7) 68.4 (61.2–75.6) 27.8 (22.9–32.7) 6.3 (2.6–10.0) 25.7 (21.1–30.3)
Missouri 73.8 (68.2–79.4) 49.1 (42.9–55.3) 8.1 (3.9–12.3) 64.8 (58.4–71.2) 34.4 (26.0–42.8) j 31.7 (23.6–39.8)
Montana 75.8 (70.9–80.7) 50.5 (44.1–56.9) 5.4 (3.0–7.8) 73.3 (67.8–78.8) 39.8 (33.1–46.5) 11.7 (7.7–15.7) 37.9 (31.6–44.2)
Nebraska 82.5 (77.5–87.5) 53.7 (45.2–62.2) 6.4 (3.3–9.5) 66.9 (60.3–73.5) 28.0 (21.1–34.9) 9.1 (4.6–13.6) 23.2 (17.0–29.4)
Nevada 85.2 (80.7–89.7) 46.7 (38.6–54.8) 7.4 (3.9–10.9) 66.1 (57.2–75.0) 25.5 (17.3–33.7) j 23.9 (16.1–31.7)
New Hampshire 87.4 (82.4–92.4) 55.1 (47.5–62.7) 5.1 (2.6–7.6) 81.8 (75.4–88.2) 41.4 (33.3–49.5) 12.0 (6.5–17.5) 38.0 (29.8–46.2)
New Jersey 80.4 (74.6–86.2) 57.3 (51.0–63.6) 6.3 (3.0–9.6) 79.0 (72.0–86.0) 32.3 (23.4–41.2) j 29.8 (20.9–38.7)
New Mexico 75.5 (70.6–80.4) 53.1 (45.3–60.9) 8.1 (5.4–10.8) 64.5 (56.4–72.6) 34.3 (29.0–39.6) 14.5 (9.8–19.2) 30.7 (24.7–36.7)
New York 78.0 (73.7–82.3) 55.5 (51.6–59.4) 8.4 (5.8–11.0) 75.6 (71.2–80.0) 35.0 (28.7–41.3) 10.1 (6.4–13.8) 32.4 (26.0–38.8)
North Carolina 79.2 (75.2–83.2) 53.7 (48.3–59.1) 7.1 (4.5–9.7) 75.9 (69.3–82.5) 31.2 (24.7–37.7) 6.2 (3.1–9.3) 29.1 (23.3–34.9)
North Dakota 73.2 (67.8–78.6) 53.8 (47.1–60.5) 8.0 (4.2–11.8) 68.3 (62.1–74.5) 28.2 (20.6–35.8) 12.4 (6.1–18.7) 25.5 (17.6–33.4)
Ohio 72.0 (68.0–76.0) 51.7 (47.7–55.7) 6.6 (4.7–8.5) 68.2 (62.5–73.9) 34.2 (28.4–40.0) 6.1 (3.5–8.7) 32.4 (26.8–38.0)
Oklahoma 73.6 (66.9–80.3) 54.9 (49.2–60.6) 7.7 (5.3–10.1) 68.5 (61.0–76.0) 35.7 (29.7–41.7) 13.3 (7.4–19.2) 29.8 (24.7–34.9)
Oregon 83.7 (78.9–88.5) 58.0 (51.6–64.4) 8.4 (5.1–11.7) 71.6 (62.2–81.0) 39.5 (30.5–48.5) 9.8 (4.6–15.0) 37.0 (28.6–45.4)
Pennsylvania 80.3 (76.2–84.4) 56.2 (51.7–60.7) 6.5 (4.2–8.8) 68.8 (64.1–73.5) 39.5 (33.6–45.4) 10.6 (6.6–14.6) 33.0 (27.1–38.9)
Rhode Island 87.3 (81.1–93.5) 62.8 (53.2–72.4) j 86.9 (79.6–94.2) 26.0 (15.8–36.2) j 25.0 (14.7–35.3)
South Carolina 74.7 (68.4–81.0) 47.5 (40.4–54.6) 5.5 (2.4–8.6) 73.5 (67.2–79.8) 46.1 (35.5–56.7) 13.5 (6.2–20.8) 42.8 (32.3–53.3)
South Dakota 78.9 (71.1–86.7) 58.0 (52.6–63.4) 10.8 (6.9–14.7) 71.1 (64.6–77.6) 29.3 (17.6–41.0) 14.9 (7.2–22.6) 27.2 (16.3–38.1)
Tennessee 74.0 (69.8–78.2) 44.1 (39.7–48.5) 7.1 (4.7–9.5) 77.7 (72.2–83.2) 28.0 (21.7–34.3) 5.8 (2.8–8.8) 25.5 (19.4–31.6)
Texas 76.1 (72.5–79.7) 50.8 (46.7–54.9) 9.0 (6.7–11.3) 66.0 (61.4–70.6) 31.2 (26.0–36.4) 9.0 (6.0–12.0) 28.1 (23.2–33.0)
Utah 77.5 (69.4–85.6) 62.7 (54.9–70.5) j 68.3 (57.8–78.8) 28.4 (17.5–39.3) j 28.4 (17.5–39.3)
Vermont 78.8 (72.6–85.0) 53.1 (45.3–60.9) j 71.1 (64.4–77.8) 49.4 (39.7–59.1) 16.8 (8.6–25.0) 47.5 (38.1–56.9)
Virginia 75.1 (68.3–81.9) 55.1 (49.1–61.1) 7.9 (3.9–11.9) 73.0 (64.7–81.3) 37.8 (28.6–47.0) 10.0 (5.6–14.4) 34.9 (25.0–44.8)
Washington 76.5 (71.1–81.9) 49.6 (43.4–55.8) 7.8 (4.4–11.2) 71.5 (65.2–77.8) 42.7 (34.5–50.9) 13.2 (7.3–19.1) 39.2 (31.1–47.3)
West Virginia 70.7 (65.8–75.6) 46.4 (39.9–52.9) 4.6 (2.9–6.3) 75.7 (70.4–81.0) 33.3 (27.6–39.0) 14.1 (10.7–17.5) 30.9 (25.3–36.5)
Wisconsin 79.4 (74.7–84.1) 50.3 (44.4–56.2) 4.6 (2.2–7.0) 79.5 (73.6–85.4) 35.7 (27.2–44.2) 8.5 (3.7–13.3) 35.0 (26.9–43.1)
Wyoming 73.6 (67.0–80.2) 53.1 (48.3–57.9) 10.0 (7.3–12.7) 64.5 (58.6–70.4) 37.2 (29.8–44.6) 12.0 (7.9–16.1) 33.1 (25.6–40.6)

Table 2. State-Specific Prevalence of Smoking Cessation and Cessation Treatment Indicators, Tobacco Use Supplement to the Current Population Survey, United States, 2018–2019a,b

a Adults who currently smoke cigarettes were defined as adults who reported smoking ≥100 cigarettes during their lifetime and now smoked cigarettes “every day” or “some days.”

b Adults who formerly smoked cigarettes were defined as adults who had smoked ≥100 cigarettes during their lifetime and reported smoking “not at all” at the time of interview.

c Adults who currently smoke cigarettes and who indicated their interest in quitting smoking by selecting a response from 2 to 10 on a 10-point scale, which ranged from 1 (not at all interested) to 10 (extremely interested).

d Adults who currently smoke cigarettes and who made a quit attempt in the past year who reported having stopped smoking for ≥1 days or reported having made a serious attempt to stop smoking (even <1 day) within the past year, and adults who formerly smoked who quit within the past year were classified as having made a quit attempt.

e Recent successful cessation was defined as adults who currently smoke and adults who formerly smoked who remained quit for ≥6 months within the past year. Recent successful cessation was assessed among adults who currently smoke and who initiated smoking at least 2 years ago, and adults who formerly smoked who reported quitting within the past year.

f Among adults who currently smoke who visited a medical doctor within the past year and adults who formerly smoked who visited a medical doctor within the year before they quit smoking, those who reported receiving advice to quit were considered as having received past-year advice to quit.

g Adults who currently smoke and adults who formerly smoked who answered yes to having used evidence-based medications (ie, nicotine patch, gum, lozenge, nasal spray, inhaler, Chantix/varenicline, Zyban/bupropion/Wellbutrin) and/or counseling (telephone help line or quit line; one-on-one in-person counseling by a health professional; stop-smoking clinic; internet or web-based program or tool, including smartphone apps and text messaging programs) during their last past-year quit attempt were classified as having used medications and/or counseling. We are not able to distinguish those who selected each item among those who selected “internet or web-based program or tool including smartphone apps and text messaging programs” and acknowledge the limitations in the definition for evidence-based counseling since the evidence is currently inadequate to infer that smartphone apps for smoking cessation are independently effective in increasing smoking cessation. See page 33 of the Surgeon General’s Report on Cessation [3].

h Adults who currently smoke and adults who formerly smoked who answered “yes” to having received counseling (telephone help line or quitline; one-on-one in-person counseling by a health professional; stop-smoking clinic; internet or web-based program or tool including smartphone apps and text messaging programs) during their last past-year quit attempt were considered as having used counseling to quit.

i Adults who currently smoke and adults who formerly smoked who answered yes to having used evidence-based medications (ie, nicotine patch, gum, lozenge, nasal spray, inhaler, Chantix/varenicline, Zyban/bupropion/Wellbutrin) during their last past-year quit attempt were considered as having used medications.

j Unweighted denominator <50 or relative standard error >30%.

CME / ABIM MOC

State-Specific Prevalence of Adult Tobacco Product Use and Cigarette Smoking Cessation Behaviors— United States, 2018-2019

  • Authors: Monica E. Cornelius, PhD; Teresa W. Wang, PhD; Ahmed Jamal, MBBS; Caitlin Loretan, MPH; Gordon Willis, PhD; Bria Graham-Glover, MPH; Linda Neff, MPH
  • CME / ABIM MOC Released: 11/2/2023
  • Valid for credit through: 11/2/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care clinicians and other healthcare professionals who care for adults who use tobacco products.

The goal of this activity is for learners to be better able to assess trends in tobacco product use and cessation behaviors among US adults.

Upon completion of this activity, participants will:

  • Distinguish current patterns in tobacco use among US adults
  • Compare US regions regarding cigarette use and the desire to quit cigarette smoking
  • Analyze tobacco cessation beliefs and behaviors in the United States
  • Evaluate how US adults use evidence-based tools to help them quit smoking


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Monica E. Cornelius, PhD

    Office on Smoking and Health National Center for Chronic Disease Prevention and Health Promotion
    Atlanta, Georgia

  • Teresa W. Wang, PhD

    Office on Smoking and Health National Center for Chronic Disease Prevention and Health Promotion
    Atlanta, Georgia

  • Ahmed Jamal, MBBS

    Office on Smoking and Health National Center for Chronic Disease Prevention and Health Promotion
    Atlanta, Georgia

  • Caitlin Loretan, MPH

    Office on Smoking and Health National Center for Chronic Disease Prevention and Health Promotion
    Atlanta, Georgia

  • Gordon Willis, PhD

    Behavioral Research Program Division of Cancer Control and Population Sciences
    National Cancer Institute
    Rockville, Maryland 

  • Bria Graham-Glover, MPH

    Center for Tobacco Products
    U.S. Food and Drug Administration
    Silver Spring, Maryland

  • Linda Neff, MPH

    Office on Smoking and Health National Center for Chronic Disease Prevention and Health Promotion
    Atlanta, Georgia

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine
    Irvine, California

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Editor

  • Camille Martin

    Editor 
    Preventing Chronic Disease
    Atlanta, Georgia

​​​​Cmpliance Reviewer

  • ​Stephanie Corder, ND, RN, CHCP

    ​​Associate Director, Accreditation and Compliance, Medscape, LLC​

    Disclosures

    ​Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.​


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Preventing Chronic Disease. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

State-Specific Prevalence of Adult Tobacco Product Use and Cigarette Smoking Cessation Behaviors— United States, 2018-2019

Authors: Monica E. Cornelius, PhD; Teresa W. Wang, PhD; Ahmed Jamal, MBBS; Caitlin Loretan, MPH; Gordon Willis, PhD; Bria Graham-Glover, MPH; Linda Neff, MPHFaculty and Disclosures

CME / ABIM MOC Released: 11/2/2023

Valid for credit through: 11/2/2024, 11:59 PM EST

processing....

Abstract

Introduction
Increasing quitting among people who smoke cigarettes is the quickest approach to reducing tobacco-related disease and death.

Methods
We analyzed data from the 2018–2019 Tobacco Use Supplement to the Current Population Survey for 137,471 adult self-respondents from all 50 US states and the District of Columbia to estimate state-specific prevalence of current tobacco product use, interest in quitting smoking, past-year quit attempts, recent successful cessation (past-year quit lasting ≥6 months), receipt of advice to quit smoking from a medical doctor, and use of cessation medications and/or counseling to quit.

Results
Prevalence of current any-tobacco use (use every day or some days) ranged from 10.2% in California to 29.0% in West Virginia. The percentage of adults who currently smoked cigarettes and were interested in quitting ranged from 68.2% in Alabama to 87.5% in Connecticut; made a past-year quit attempt ranged from 44.1% in Tennessee to 62.8% in Rhode Island; reported recent successful cessation ranged from 4.6% in West Virginia and Wisconsin to 10.8% in South Dakota; received advice to quit from a medical doctor ranged from 63.3% in Colorado to 86.9% in Rhode Island; and used medications and/or counseling to quit ranged from 25.5% in Nevada to 50.1% in Massachusetts. Several states with the highest cigarette smoking prevalence reported the lowest prevalence of interest in quitting, quit attempts, receipt of advice to quit, and use of counseling and/or medication, and the highest prevalence of e-cigarette, smokeless tobacco, and cigar use.

Conclusion
Adults who smoke struggle with smoking cessation and could benefit from additional intervention.